id
stringlengths
14
14
page_content
stringlengths
10
2.06k
source
stringclasses
1 value
5d8c934a2048-0
DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS FIFTH EDITION DSM-5™
dsm5.pdf
415a51d548ec-0
American Psychiatric Association Officers 2012–2013 PRESIDENT DILIP V. J ESTE , M.D. PRESIDENT -ELECT JEFFREY A. L IEBERMAN , M.D. TREASURER DAVID FASSLER , M.D. SECRETARY ROGER PEELE , M.D. Assembly SPEAKER R. S COTT BENSON , M.D. SPEAKER -ELECT MELINDA L. Y OUNG , M.D. Board of Trustees JEFFREY AKAKA , M.D. CAROL A. B ERNSTEIN , M.D. BRIAN CROWLEY , M.D. ANITA S. E VERETT , M.D. JEFFREY GELLER , M.D., M.P.H. MARC DAVID GRAFF , M.D. JAMES A. G REENE , M.D. JUDITH F. K ASHTAN , M.D. MOLLY K. M CVOY, M.D. JAMES E. N ININGER , M.D. JOHN M. O LDHAM , M.D. ALAN F. S CHATZBERG , M.D. ALIK S. W IDGE , M.D., P H.D. ERIK R. V ANDERLIP , M.D., MEMBER -IN-TRAINING TRUSTEE -ELECT
dsm5.pdf
31f28e62a544-0
Washington, DC London, EnglandDIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS FIFTH EDITION DSM-5™
dsm5.pdf
2c134e9439dc-0
Copyright © 2013 American Psychiatric Association DSM and DSM-5 are trademarks of the American Psychiatric Association. Use of these terms is prohibited without perm ission of the American Psychiatric Association. ALL RIGHTS RESERVED. Unless auth orized in writing by the APA, no part of this book may be reproduced or used in a manner inconsistent with the APA’s copyright. This prohibition applies to unauthorized uses or reproductions in any form, including electronic applications. Correspondence regarding copyright permissions should be directed to DSM Permissions, American Psychiatric Publishing, 1000 Wilso n Boulevard, Suite 1825, Arlington, VA 22209- 3901. Manufactured in the United States of America on acid-free paper. ISBN 978-0-89042-554-1 (Hardcover) 2nd printing June 2013 ISBN 978-0-89042-555-8 (Paperba ck) 2nd prin ting June 2013 American Psychiatric Association 1000 Wilson Boulevard Arlington, VA 22209-3901 www.psych.org The correct citation for this book is American Psychiatric Association: Diagnostic and Statisti- cal Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Associa- tion, 2013. Library of Congress Cataloging-in-Publication Data Diagnostic and statistical manual of mental disorders : DSM-5. — 5th ed. p. ; cm. DSM-5 DSM-V Includes index. ISBN 978-0-89042-554-1 (hardcover : alk. paper) — ISBN 978-0-89042-555-8 (pbk. : alk. paper) I. American Psychiatric Association. II. American Psychiatric Association. DSM-5 Task Force.
dsm5.pdf
2c134e9439dc-1
III. Title: DSM-5. IV. Title: DSM-V. [DNLM: 1. Diagnostic and statistical manual of mental disorders. 5th ed. 2. Mental Disorders— classification. 3. Mental Disorders—diagnosis. WM 15] RC455.2.C4 616.89'075—dc23 2013011061 British Library Cataloguing in Publication Data A CIP record is available from the British Library. Text Design—Tammy J. Cordova Manufacturing—R.R. Donnelley
dsm5.pdf
d37ebd147212-0
Contents DSM-5 Classification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .xli Section I DSM-5 Basics Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 Use of the Manual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19 Cautionary Statement for Forensic Us e of DSM-5 . . . . . . . . . . . .25 Section II Diagnostic Criteria and Codes Neurodevelopmental Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . .31 Schizophrenia Spectrum and Other Psychotic Disorders . . . . . .87 Bipolar and Related Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . .123 Depressive Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .155 Anxiety Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .189
dsm5.pdf
d37ebd147212-1
Obsessive-Compulsive and Re lated Disorders . . . . . . . . . . . . .235 Trauma- and Stressor-Related Disorders . . . . . . . . . . . . . . . . . .265 Dissociative Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .291 Somatic Symptom and Related Disorders . . . . . . . . . . . . . . . . .309 Feeding and Eating Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . .329 Elimination Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .355 Sleep-Wake Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .361 Sexual Dysfunctions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .423 Gender Dysphoria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .451
dsm5.pdf
2c0cb3036a0f-0
Disruptive, Impulse-Control, and Con duct Disorders . . . . . . . . 461 Substance-Related and Addictive Disord ers . . . . . . . . . . . . . . . 481 Neurocognitive Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591 Personality Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 645 Paraphilic Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 685 Other Mental Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 707 Medication-Induced Movement Disorders and Other Adverse Effects of Medication . . . . . . . . . . . . . . . . 709 Other Conditions That May Be a Fo cus of Clinical Attention . . 715 Section III Emerging Measures and Models Assessment Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 733 Cultural Formulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 749 Alternative DSM-5 Model for Personality Disorder s . . . . . . . . . 761
dsm5.pdf
2c0cb3036a0f-1
Conditions for Further Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 783 Appendix Highlights of Ch anges From DSM-IV to DSM-5 . . . . . . . . . . . . . 809 Glossary of Technical Terms . . . . . . . . . . . . . . . . . . . . . . . . . . . . 817 Glossary of Cultural Concepts of Dist ress . . . . . . . . . . . . . . . . . 833 Alphabetical Listing of DSM-5 Diagno ses and Codes (ICD-9-CM and ICD-10-CM). . . . . . . . . . . . . . . . . . . . . . . . . . . . 839 Numerical Listing of DS M-5 Diagnoses and Codes (ICD-9-CM) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 863 Numerical Listing of DS M-5 Diagnoses and Codes (ICD-10-CM) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 877 DSM-5 Advisors and Other Contributors . . . . . . . . . . . . . . . . . . 897
dsm5.pdf
2c0cb3036a0f-2
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 917
dsm5.pdf
6001a2cc7a68-0
DSM-5 Task Force DAVID J. K UPFER , M.D. Task Force Chair DARREL A. R EGIER , M.D., M.P.H. Task Force Vice-Chair William E. Narrow, M.D., M.P.H., Research DirectorSusan K. Schultz, M.D., Text Editor Emily A. Kuhl, Ph.D., APA Text Editor Dan G. Blazer, M.D., Ph.D., M.P.H. Jack D. Burke Jr., M.D., M.P.H. William T. Carpenter Jr., M.D. F. Xavier Castellanos, M.D. Wilson M. Compton, M.D., M.P.E. Joel E. Dimsdale, M.D. Javier I. Escobar, M.D., M.Sc. Jan A. Fawcett, M.D. Bridget F. Grant, Ph.D., Ph.D. (2009–) Steven E. Hyman, M.D. (2007–2012) Dilip V. Jeste, M.D. (2007–2011) Helena C. Kraemer, Ph.D. Daniel T. Mamah, M.D., M.P.E. James P. McNulty, A.B., Sc.B. Howard B. Moss, M.D. (2007–2009)Charles P. O’Brien, M.D., Ph.D. Roger Peele, M.D. Katharine A. Phillips, M.D. Daniel S. Pine, M.D. Charles F. Reynolds III, M.D. Maritza Rubio-Stipec, Sc.D. David Shaffer, M.D. Andrew E. Skodol II, M.D. Susan E. Swedo, M.D.
dsm5.pdf
6001a2cc7a68-1
Susan E. Swedo, M.D. B. Timothy Walsh, M.D. Philip Wang, M.D., Dr.P.H. (2007–2012) William M. Womack, M.D. Kimberly A. Yonkers, M.D. Kenneth J. Zucker, Ph.D. Norman Sartorius, M.D., Ph.D., Consultant APA Division of Research Staff on DSM-5 Darrel A. Regier, M.D., M.P.H., Director, Division of Research William E. Narrow, M.D., M.P.H., Associate Director Emily A. Kuhl, Ph.D., Senior Science Writer; Staff Text Editor Diana E. Clarke, Ph.D., M.Sc., Research Statistician Lisa H. Greiner, M.S.S.A., DSM-5 Field Trials Project Manager Eve K. Moscicki, Sc.D., M.P.H., Director, Practice Research Network S. Janet Kuramoto, Ph.D. M.H.S., Senior Scientific Research Associate, Practice Research Network Amy Porfiri, M.B.A. Director of Finance and AdministrationJennifer J. Shupinka, Assistant Director, DSM Operations Seung-Hee Hong, DSM Senior Research Associate Anne R. Hiller, DSM Research Associate Alison S. Beale, DSM Research Associate Spencer R. Case, DSM Research Associate Joyce C. West, Ph.D., M.P.P., Health Policy Research Director, Practice Research Network Farifteh F. Duffy, Ph.D., Quality Care Research Director, Practice Research Network Lisa M. Countis, Field Operations Manager, Practice Research Network Christopher M. Reynolds, Executive Assistant
dsm5.pdf
6001a2cc7a68-2
Manager, Practice Research Network Christopher M. Reynolds, Executive Assistant APA Office of the Medical Director JAMES H. S CULLY JR., M.D. Medical Director and CEO
dsm5.pdf
92cb8317dce6-0
Editorial and Coding Consultants Michael B. First, M.D. Maria N. Ward, M.Ed., RHIT, CCS-P DSM-5 Work Groups ADHD and Disruptive Behavior Disorders DAVID SHAFFER , M.D. Chair F. X AVIER CASTELLANOS , M.D. Co-Chair Paul J. Frick, Ph.D., Text Coordinator Glorisa Canino, Ph.D. Terrie E. Moffitt, Ph.D. Joel T. Nigg, Ph.D. Luis Augusto Rohde, M.D., Sc.D. Rosemary Tannock, Ph.D. Eric A. Taylor, M.B. Richard Todd, Ph.D., M.D. (d. 2008) Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders KATHARINE A. P HILLIPS , M.D. Chair Michelle G. Craske, Ph.D., Text Coordinator J. Gavin Andrews, M.D. Susan M. Bögels, Ph.D. Matthew J. Friedman, M.D., Ph.D. Eric Hollander, M.D. (2007–2009) Roberto Lewis-Fernández, M.D., M.T.S. Robert S. Pynoos, M.D., M.P.H.Scott L. Rauch, M.D. H. Blair Simpson, M.D., Ph.D. David Spiegel, M.D. Dan J. Stein, M.D., Ph.D. Murray B. Stein, M.D. Robert J. Ursano, M.D. Hans-Ulrich Wittchen, Ph.D. Childhood and Adolescent Disorders DANIEL S. P INE, M.D. Chair
dsm5.pdf
92cb8317dce6-1
DANIEL S. P INE, M.D. Chair Ronald E. Dahl, M.D. E. Jane Costello, Ph.D. (2007–2009) Regina Smith James, M.D. Rachel G. Klein, Ph.D.James F. Leckman, M.D. Ellen Leibenluft, M.D. Judith H. L. Rapoport, M.D. Charles H. Zeanah, M.D. Eating Disorders B. T IMOTHY WALSH , M.D. Chair Stephen A. Wonderlich, Ph.D., Text Coordinator Evelyn Attia, M.D. Anne E. Becker, M.D., Ph.D., Sc.M. Rachel Bryant-Waugh, M.D. Hans W. Hoek, M.D., Ph.D.Richard E. Kreipe, M.D. Marsha D. Marcus, Ph.D. James E. Mitchell, M.D. Ruth H. Striegel-Moore, Ph.D. G. Terence Wilson, Ph.D. Barbara E. Wolfe, Ph.D. A.P.R.N.
dsm5.pdf
bc0226764c4c-0
Mood Disorders JAN A. F AWCETT , M.D. Chair Ellen Frank, Ph.D., Text Coordinator Jules Angst, M.D. (2007–2008) William H. Coryell, M.D. Lori L. Davis, M.D. Raymond J. DePaulo, M.D. Sir David Goldberg, M.D. James S. Jackson, Ph.D.Kenneth S. Kendler, M.D. (2007–2010) Mario Maj, M.D., Ph.D. Husseini K. Manji, M.D. (2007–2008) Michael R. Phillips, M.D. Trisha Suppes, M.D., Ph.D. Carlos A. Zarate, M.D. Neurocognitive Disorders DILIP V. J ESTE , M.D. (2007–2011) Chair Emeritus DAN G. B LAZER , M.D., P H.D., M.P.H. Chair RONALD C. P ETERSEN , M.D., P H.D. Co-Chair Mary Ganguli, M.D., M.P.H., Text Coordinator Deborah Blacker, M.D., Sc.D. Warachal Faison, M.D. (2007–2008)Igor Grant, M.D. Eric J. Lenze, M.D. Jane S. Paulsen, Ph.D. Perminder S. Sachdev, M.D., Ph.D. Neurodevelopmental Disorders SUSAN E. S WEDO , M.D. Chair Gillian Baird, M.A., M.B., B.Chir., Text Coordinator Edwin H. Cook Jr., M.D.
dsm5.pdf
bc0226764c4c-1
Text Coordinator Edwin H. Cook Jr., M.D. Francesca G. Happé, Ph.D. James C. Harris, M.D. Walter E. Kaufmann, M.D. Bryan H. King, M.D. Catherine E. Lord, Ph.D.Joseph Piven, M.D. Sally J. Rogers, Ph.D. Sarah J. Spence, M.D., Ph.D. Rosemary Tannock, Ph.D. Fred Volkmar, M.D. (2007–2009) Amy M. Wetherby, Ph.D. Harry H. Wright, M.D. Personality and Personality Disorders1 ANDREW E. S KODOL , M.D. Chair JOHN M. O LDHAM , M.D. Co-Chair Robert F. Krueger, Ph.D., Text Coordinator Renato D. Alarcon, M.D., M.P.H. Carl C. Bell, M.D. Donna S. Bender, Ph.D.Lee Anna Clark, Ph.D. W. John Livesley, M.D., Ph.D. (2007–2012) Leslie C. Morey, Ph.D. Larry J. Siever, M.D. Roel Verheul, Ph.D. (2008–2012) 1The members of the Personality and Personality Disorders Work Group are responsible for the alternative DSM-5 model for personality disorders that is included in Section III. The Section II personality disorders criteria and text (with upda ting of the text) are retained from DSM-IV-TR.
dsm5.pdf
1605fc581f0f-0
Psychotic Disorders WILLIAM T. C ARPENTER JR., M.D. Chair Deanna M. Barch, Ph.D., Text Coordinator Juan R. Bustillo, M.D. Wolfgang Gaebel, M.D. Raquel E. Gur, M.D., Ph.D. Stephan H. Heckers, M.D.Dolores Malaspina, M.D., M.S.P.H. Michael J. Owen, M.D., Ph.D. Susan K. Schultz, M.D. Rajiv Tandon, M.D. Ming T. Tsuang, M.D., Ph.D. Jim van Os, M.D. Sexual and Gender Identity Disorders KENNETH J. Z UCKER , PH.D. Chair Lori Brotto, Ph.D., Text Coordinator Irving M. Binik, Ph.D. Ray M. Blanchard, Ph.D. Peggy T. Cohen-Kettenis, Ph.D. Jack Drescher, M.D. Cynthia A. Graham, Ph.D.Martin P. Kafka, M.D. Richard B. Krueger, M.D. Niklas Långström, M.D., Ph.D. Heino F.L. Meyer-Bahlburg, Dr. rer. nat. Friedemann Pfäfflin, M.D. Robert Taylor Segraves, M.D., Ph.D. Sleep-Wake Disorders CHARLES F. R EYNOLDS III, M.D. Chair Ruth M. O’Hara, Ph.D., Text Coordinator Charles M. Morin, Ph.D. Allan I. Pack, Ph.D.Kathy P. Parker, Ph.D., R.N. Susan Redline, M.D., M.P.H.
dsm5.pdf
1605fc581f0f-1
Susan Redline, M.D., M.P.H. Dieter Riemann, Ph.D. Somatic Symptom Disorders JOEL E. D IMSDALE , M.D. Chair James L. Levenson, M.D., Text Coordinator Arthur J. Barsky III, M.D. Francis Creed, M.D. Nancy Frasure-Smith, Ph.D. (2007–2011)Michael R. Irwin, M.D. Francis J. Keefe, Ph.D. (2007–2011) Sing Lee, M.D. Michael Sharpe, M.D. Lawson R. Wulsin, M.D. Substance-Related Disorders CHARLES P. O’B RIEN , M.D., P H.D. Chair THOMAS J. C ROWLEY , M.D. Co-Chair Wilson M. Compton, M.D., M.P.E., Text Coordinator Marc Auriacombe, M.D. Guilherme L. G. Borges, M.D., Dr.Sc. Kathleen K. Bucholz, Ph.D. Alan J. Budney, Ph.D. Bridget F. Grant, Ph.D., Ph.D. Deborah S. Hasin, Ph.D.Thomas R. Kosten, M.D. (2007–2008) Walter Ling, M.D. Spero M. Manson, Ph.D. (2007-2008) A. Thomas McLellan, Ph.D. (2007–2008) Nancy M. Petry, Ph.D. Marc A. Schuckit, M.D. Wim van den Brink, M.D., Ph.D. (2007–2008)
dsm5.pdf
e76234ec1ce7-0
DSM-5 Study Groups Diagnostic Spect ra and DSM/ICD Harmonization STEVEN E. H YMAN , M.D. Chair (2007–2012) William T. Carpenter Jr., M.D. Wilson M. Compton, M.D., M.P.E. Jan A. Fawcett, M.D. Helena C. Kraemer, Ph.D. David J. Kupfer, M.D.William E. Narrow, M.D., M.P.H. Charles P. O’Brien, M.D., Ph.D. John M. Oldham, M.D. Katharine A. Phillips, M.D. Darrel A. Regier, M.D., M.P.H. Lifespan Developmental Approaches ERIC J. L ENZE , M.D. Chair SUSAN K. S CHULTZ , M.D. Chair Emeritus DANIEL S. P INE, M.D. Chair Emeritus Dan G. Blazer, M.D., Ph.D., M.P.H. F. Xavier Castellanos, M.D. Wilson M. Compton, M.D., M.P.E.Daniel T. Mamah, M.D., M.P.E. Andrew E. Skodol II, M.D. Susan E. Swedo, M.D. Gender and Cross-Cultural Issues KIMBERLY A. Y ONKERS , M.D. Chair ROBERTO LEWIS -FERNÁNDEZ , M.D., M.T.S. Co-Chair, Cross-Cultural Issues Renato D. Alarcon, M.D., M.P.H. Diana E. Clarke, Ph.D., M.Sc. Javier I. Escobar, M.D., M.Sc.
dsm5.pdf
e76234ec1ce7-1
Javier I. Escobar, M.D., M.Sc. Ellen Frank, Ph.D. James S. Jackson, Ph.D. Spiro M. Manson, Ph.D. (2007–2008) James P. McNulty, A.B., Sc.B.Leslie C. Morey, Ph.D. William E. Narrow, M.D., M.P.H. Roger Peele, M.D. Philip Wang, M.D., Dr.P.H. (2007–2012) William M. Womack, M.D. Kenneth J. Zucker, Ph.D. Psychiatric/General Medical Interface LAWSON R. W ULSIN , M.D. Chair Ronald E. Dahl, M.D. Joel E. Dimsdale, M.D. Javier I. Escobar, M.D., M.Sc. Dilip V. Jeste, M.D. (2007–2011) Walter E. Kaufmann, M.D.Richard E. Kreipe, M.D. Ronald C. Petersen, Ph.D., M.D. Charles F. Reynolds III, M.D. Robert Taylor Segraves, M.D., Ph.D. B. Timothy Walsh, M.D.
dsm5.pdf
db835f9be4b5-0
Impairment and Disability JANE S. P AULSEN , PH.D. Chair J. Gavin Andrews, M.D. Glorisa Canino, Ph.D. Lee Anna Clark, Ph.D. Diana E. Clarke, Ph.D., M.Sc. Michelle G. Craske, Ph.D.Hans W. Hoek, M.D., Ph.D. Helena C. Kraemer, Ph.D. William E. Narrow, M.D., M.P.H. David Shaffer, M.D. Diagnostic Assessm ent Instruments JACK D. B URKE JR., M.D., M.P.H. Chair Lee Anna Clark, Ph.D. Diana E. Clarke, Ph.D., M.Sc. Bridget F. Grant, Ph.D., Ph.D.Helena C. Kraemer, Ph.D. William E. Narrow, M.D., M.P.H. David Shaffer, M.D. DSM-5 Research Group WILLIAM E. N ARROW , M.D., M.P.H. Chair Jack D. Burke Jr., M.D., M.P.H. Diana E. Clarke, Ph.D., M.Sc. Helena C. Kraemer, Ph.D.David J. Kupfer, M.D. Darrel A. Regier, M.D., M.P.H. David Shaffer, M.D. Course Specifiers and Glossary WOLFGANG GAEBEL , M.D. Chair Ellen Frank, Ph.D. Charles P. O’Brien, M.D., Ph.D. Norman Sartorius, M.D., Ph.D., Consultant Susan K. Schultz, M.D.Dan J. Stein, M.D., Ph.D. Eric A. Taylor, M.B.
dsm5.pdf
db835f9be4b5-1
Eric A. Taylor, M.B. David J. Kupfer, M.D. Darrel A. Regier, M.D., M.P.H.
dsm5.pdf
6d36277c0179-0
xiiiDSM-5 Classification Before each disorder name, ICD-9-CM code s are provided, followe d by ICD-10-CM codes in parentheses. Blank lines indicate that eith er the ICD-9-CM or the ICD-10-CM code is not applicable. For some disorders, the code can be indicated only according to the subtype or specifier. ICD-9-CM codes are to be used for coding purposes in the United States through Sep- tember 30, 2014. ICD-10-CM codes are to be used starting October 1, 2014. Following chapter titles and disorder name s, page numbers for the corresponding text or criteria are incl uded in parentheses. Note for all mental disorders due to another medical condition: Indicate the name of the other medical condition in the name of th e mental disorder due to [the medical condi- tion]. The code and name for the other medica l condition should be listed first immedi- ately before the mental disorder due to the medical condition. Neurodevelopmental Disorders (31) Intellectual Disabilities (33) ___.__ (___.__) Intellectual Disability (Intelle ctual Developmental Disorder) (33) Specify current severity: 317 (F70) Mild 318.0 (F71) Moderate 318.1 (F72) Severe 318.2 (F73) Profound 315.8 (F88) Global Developmental Delay (41) 319 (F79) Unspecified Intellectual Disability (Intellectual Developmental Disorder) (41) Communication Disorders (41) 315.32 (F80.2) Language Disorder (42) 315.39 (F80.0) Speech Sound Disorder (44)
dsm5.pdf
6d36277c0179-1
315.39 (F80.0) Speech Sound Disorder (44) 315.35 (F80.81) Childhood-Onset Fluency Disorder (Stuttering) (45) Note: Later-onset cases are diagnosed as 307.0 (F98.5) adult-onset fluency disorder. 315.39 (F80.89) Social (Pragmatic) Communication Disorder (47) 307.9 (F80.9) Unspecified Communication Disorder (49)
dsm5.pdf
88e5281eaa4e-0
xiv DSM-5 Classification Autism Spectrum Disorder (50) 299.00 (F84.0) Autism Spectrum Disorder (50) Specify if: Associated with a known medic al or genetic condition or envi- ronmental factor; Associ ated with another neurodevelopmental, men- tal, or behavioral disorder Specify current severity for Criterion A and Criterion B: Requiring very substantial support, Requiring substantial support, Requiring support Specify if: With or without accompanyi ng intellectual impairment, With or without accompanying language impairment, With catatonia (use additional code 293.89 [F06.1]) Attention-Deficit/Hyperactivity Disorder (59) ___.__ (___.__) Attention-Deficit/Hyperactivity Disorder (59) Specify whether: 314.01 (F90.2) Combined presentation 314.00 (F90.0) Predominantly inattentive presentation 314.01 (F90.1) Predominantly hyperactive/impulsive presentation Specify if: In partial remission Specify current severity: Mild, Moderate, Severe 314.01 (F90.8) Other Specified Attention-Deficit/Hyperactivity Disorder (65) 314.01 (F90.9) Unspecified Attention-Deficit/Hyperactivity Disorder (66) Specific Learning Disorder (66) ___.__ (___.__) Specific Learning Disorder (66) Specify if: 315.00 (F81.0) With impairment in reading (specify if with word reading accuracy, reading rate or fluency, reading comprehension) 315.2 (F81.81) With impairment in written expression ( specify if with spelling accuracy, grammar and punctu ation accuracy, clarity or organization of written expression)
dsm5.pdf
88e5281eaa4e-1
accuracy, grammar and punctu ation accuracy, clarity or organization of written expression) 315.1 (F81.2) With impairment in mathematics ( specify if with number sense, memorization of arithmetic facts, accurate or fluent calculation, accurate math reasoning) Specify current severity: Mild, Moderate, Severe Motor Disorders (74) 315.4 (F82) Developmental Coordination Disorder (74) 307.3 (F98.4) Stereotypic Movement Disorder (77) Specify if: With self-injurious behavior , Without self-injurious behavior Specify if: Associated with a known medical or genetic condition, neuro- developmental disorder, or environmental factor Specify current severity: Mild, Moderate, Severe Tic Disorders 307.23 (F95.2) Tourette's Disorder (81) 307.22 (F95.1) Persistent (Chronic) Motor or Vocal Tic Disorder (81) Specify if: With motor tics only, With vocal tics only
dsm5.pdf
ae3692a494c9-0
DSM-5 Classification xv 307.21 (F95.0) Provisional Tic Disorder (81) 307.20 (F95.8) Other Specified Tic Disorder (85) 307.20 (F95.9) Unspecified Tic Disorder (85) Other Neurodevelopmental Disorders (86) 315.8 (F88) Other Specified Neurodevelopmental Disorder (86) 315.9 (F89) Unspecified Neurodevelopmental Disorder (86) Schizophrenia Spectrum and Other Psychotic Disorders (87) The following specifiers apply to Schizophre nia Spectrum and Othe r Psychotic Disorders where indicated: aSpecify if: The following course specifiers are only to be used after a 1-year duration of the dis- order: First episode, currently in acute episode; First episode, currently in partial remission; First episode, currently in full remission; Multiple episodes, currently in acute episode; Mul- tiple episodes, currently in partial remission; Multiple episodes, currently in full remission; Continuous; Unspecified bSpecify if: With catatonia (use additional code 293.89 [F06.1]) cSpecify current severity of delusions, hallucinations, disorganized speech, abnormal psycho- motor behavior, negative symptoms, impaired cognition, depression, and mania symptoms 301.22 (F21) Schizotypal (Personality) Disorder (90) 297.1 (F22) Delusional Disordera, c (90) Specify whether: Erotomanic type, Grandiose type, Jealous type, Persecu- tory type, Somatic type, Mi xed type, Unspecified type Specify if: With bizarre content
dsm5.pdf
ae3692a494c9-1
Specify if: With bizarre content 298.8 (F23) Brief Psychotic Disorderb, c (94) Specify if: With marked stressor(s), Without marked stressor(s), With postpartum onset 295.40 (F20.81) Schizophreniform Disorderb, c (96) Specify if: With good prognostic featur es, Without good prognostic fea- tures 295.90 (F20.9) Schizophreniaa, b, c (99) ___.__ (___.__) Schizoaffective Disordera, b, c (105) Specify whether: 295.70 (F25.0) Bipolar type 295.70 (F25.1) Depressive type ___.__ (___.__) Substance/Medication-Ind uced Psychotic Disorderc (110) Note: See the criteria set and corresponding recording procedures for substance-specific codes and ICD-9-CM and ICD-10-CM coding. Specify if: With onset during intoxicatio n, With onset during withdrawal ___.__ (___.__) Psychotic Disorder Due to Another Medical Conditionc (115) Specify whether: 293.81 (F06.2) With delusions 293.82 (F06.0) With hallucinations
dsm5.pdf
6611a946fb19-0
xvi DSM-5 Classification 293.89 (F06.1) Catatonia Associated With Anothe r Mental Disorder (Catatonia Specifier) (119) 293.89 (F06.1) Catatonic Disorder Due to Another Medical Condition (120) 293.89 (F06.1) Unspecified Catatonia (121) Note: Code first 781.99 (R29.818) other symptoms involving nervous and musculoskeletal systems. 298.8 (F28) Other Specified Schizophrenia Spectrum and Other Psychotic Disorder (122) 298.9 (F29) Unspecified Schizophrenia Spectrum and Other Psychotic Disorder (122) Bipolar and Related Disorders (123) The following specifiers apply to Bipolar and Related Disorders where indicated: aSpecify: With anxious distress ( specify current severity: mild, modera te, moderate-severe, severe); With mixed features; With rapid cycling; With melancholic features; With atypical features; With mood-congruent psychotic features; With mood-incongruent psychotic features; With catatonia (use additional code 293.89 [F06.1]); With peripartum onset; With seasonal pattern ___.__ (___.__) Bipolar I Disordera (123) ___.__ (___.__) Current or most recent episode manic 296.41 (F31.11) Mild 296.42 (F31.12) Moderate 296.43 (F31.13) Severe 296.44 (F31.2) With psychotic features 296.45 (F31.73) In partial remission 296.46 (F31.74) In full remission
dsm5.pdf
6611a946fb19-1
296.46 (F31.74) In full remission 296.40 (F31.9) Unspecified 296.40 (F31.0) Current or most recent episode hypomanic 296.45 (F31.71) In partial remission 296.46 (F31.72) In full remission 296.40 (F31.9) Unspecified ___.__ (___.__) Current or most recent episode depressed 296.51 (F31.31) Mild 296.52 (F31.32) Moderate 296.53 (F31.4) Severe 296.54 (F31.5) With psychotic features 296.55 (F31.75) In partial remission 296.56 (F31.76) In full remission 296.50 (F31.9) Unspecified 296.7 (F31.9) Current or most recent episode unspecified 296.89 (F31.81) Bipolar II Disordera (132) Specify current or most recent ep isode: Hypomanic, Depressed Specify course if full criteria for a mood episode are not currently met: In partial remission, In full remission Specify severity if full criteria for a mood episode are currently met: Mild, Moderate, Severe
dsm5.pdf
94e968134e15-0
DSM-5 Classification xvii 301.13 (F34.0) Cyclothymic Disorder (139) Specify if: With anxious distress ___.__ (___.__) Substance/Medication-Induced Bipo lar and Related Disorder (142) Note: See the criteria set and corresponding recording procedures for substance-specific codes and ICD-9-CM and ICD-10-CM coding. Specify if: With onset during intoxicatio n, With onset during withdrawal 293.83 (___.__) Bipolar and Related Disorder Due to Another Medical Condition (145) Specify if: (F06.33) With manic features (F06.33) With manic- or hypomanic-like episode (F06.34) With mixed features 296.89 (F31.89) Other Specified Bipolar and Related Disorder (148) 296.80 (F31.9) Unspecified Bipolar and Related Disorder (149) Depressive Disorders (155) The following specifiers apply to Depressive Disorders where indicated: aSpecify: With anxious distress ( specify current severity: mild, moderate, moderate-severe, severe); With mixed features; With melancholic features; With atypical features; With mood- congruent psychotic features; With mood-incongruent psych otic features; Wi th catatonia (use additional code 293.89 [F06.1]); With peripartum on set; With seasonal pattern 296.99 (F34.8) Disruptive Mood Dysregulation Disorder (156) ___.__ (___.__) Major Depressive Disordera (160) ___.__ (___.__) Single episode 296.21 (F32.0) Mild 296.22 (F32.1) Moderate
dsm5.pdf
94e968134e15-1
296.22 (F32.1) Moderate 296.23 (F32.2) Severe 296.24 (F32.3) With psychotic features 296.25 (F32.4) In partial remission 296.26 (F32.5) In full remission 296.20 (F32.9) Unspecified ___.__ (___.__) Recurrent episode 296.31 (F33.0) Mild 296.32 (F33.1) Moderate 296.33 (F33.2) Severe 296.34 (F33.3) With psychotic features 296.35 (F33.41) In partial remission 296.36 (F33.42) In full remission 296.30 (F33.9) Unspecified 300.4 (F34.1) Persistent Depressive Disorder (Dysthymia)a (168) Specify if: In partial remission, In full remission Specify if: Early onset, Late onset Specify if: With pure dysthymic syndrome ; With persistent major depres- sive episode; With intermittent ma jor depressive epis odes, with current
dsm5.pdf
99e4df7fe792-0
xviii DSM-5 Classification episode; With intermittent major depressive episodes, without current episode Specify current severity: Mild, Moderate, Severe 625.4 (N94.3) Premenstrual Dysphoric Disorder (171) ___.__ (___.__) Substance/Medication-Induced Depressive Disorder (175) Note: See the criteria set and corresponding recording procedures for substance-specific codes and IC D-9-CM and ICD-10-CM coding. Specify if: With onset during intoxication, With onset during withdrawal 293.83 (___.__) Depressive Disorder Due to Another Medical Condition (180) Specify if: (F06.31) With depressive features (F06.32) With major depressive-like episode (F06.34) With mixed features 311 (F32.8) Other Specified Depressive Disorder (183) 311 (F32.9) Unspecified Depressive Disorder (184) Anxiety Disorders (189) 309.21 (F93.0) Separation Anxiety Disorder (190) 313.23 (F94.0) Selective Mutism (195) 300.29 (___.__) Specific Phobia (197) Specify if: (F40.218) Animal (F40.228) Natural environment (___.__) Blood-injection-injury (F40.230) Fear of blood (F40.231) Fear of injections and transfusions (F40.232) Fear of other medical care (F40.233) Fear of injury (F40.248) Situational (F40.298) Other 300.23 (F40.10) Social Anxiety Disorder (Social Phobia) (202) Specify if: Performance only
dsm5.pdf
99e4df7fe792-1
Specify if: Performance only 300.01 (F41.0) Panic Disorder (208) ___.__ (___.__) Panic Attack Specifier (214) 300.22 (F40.00) Agoraphobia (217) 300.02 (F41.1) Generalized Anxiety Disorder (222) ___.__ (___.__) Substance/Medication-Induced Anxiety Disorder (226) Note: See the criteria set and corresponding recording procedures for substance-specific codes and IC D-9-CM and ICD-10-CM coding. Specify if: With onset during intoxicatio n, With onset during withdrawal, With onset after medication use
dsm5.pdf
91b9d89bc31f-0
DSM-5 Classification xix 293.84 (F06.4) Anxiety Disorder Due to Anot her Medical Condition (230) 300.09 (F41.8) Other Specified Anxiety Disorder (233) 300.00 (F41.9) Unspecified Anxiety Disorder (233) Obsessive-Compulsive and Related Disorders (235) The following specifier applies to Obsessive-Compulsive and Rela ted Disorders where indicated: aSpecify if: With good or fair insight, With poor insight, With absent insight/delusional beliefs 300.3 (F42) Obsessive-Compulsive Disordera (237) Specify if: Tic-related 300.7 (F45.22) Body Dysmorphic Disordera (242) Specify if: With muscle dysmorphia 300.3 (F42) Hoarding Disordera (247) Specify if: With excessive acquisition 312.39 (F63.3) Trichotillomania (Hair-Pulling Disorder) (251) 698.4 (L98.1) Excoriation (Skin-Picking) Disorder (254) ___.__ (___.__) Substance/Medication-Induced Obsessive-Compulsive and Related Disorder (257) Note: See the criteria set and corresponding recording procedures for substance-specific codes and ICD-9-CM and ICD-10-CM coding. Specify if: With onset during intoxicatio n, With onset during withdrawal, With onset after medication use 294.8 (F06.8) Obsessive-Compulsive and Related Disorder Due to Another Medical Condition (260) Specify if: With obsessive-compulsive disorder–like symptoms, With
dsm5.pdf
91b9d89bc31f-1
Specify if: With obsessive-compulsive disorder–like symptoms, With appearance preoccupations, With hoarding symptoms, With hair- pulling symptoms, With skin-picking symptoms 300.3 (F42) Other Specified Obsessive-Compulsive and Related Disorder (263) 300.3 (F42) Unspecified Obsessive-Compulsive and Related Disorder (264) Trauma- and Stressor-Related Disorders (265) 313.89 (F94.1) Reactive Attachment Disorder (265) Specify if: Persistent Specify current severity: Severe 313.89 (F94.2) Disinhibited Social Enga gement Disorder (268) Specify if: Persistent Specify current severity: Severe 309.81 (F43.10) Posttraumatic Stress Disorder (includes Posttraumatic Stress Disorder for Children 6 Years and Younger) (271) Specify whether: With dissociative symptoms Specify if: With delayed expression 308.3 (F43.0) Acute Stress Disorder (280)
dsm5.pdf
a829f62eda84-0
xx DSM-5 Classification ___.__ (___.__) Adjustment Disorders (286) Specify whether: 309.0 (F43.21) With depressed mood 309.24 (F43.22) With anxiety 309.28 (F43.23) With mixed anxiety and depressed mood 309.3 (F43.24) With disturbance of conduct 309.4 (F43.25) With mixed disturbance of emotions and conduct 309.9 (F43.20) Unspecified 309.89 (F43.8) Other Specified Trauma- and Stressor-Related Disorder (289) 309.9 (F43.9) Unspecified Trauma- and Stress or-Related Disorder (290) Dissociative Disorders (291) 300.14 (F44.81) Dissociative Identity Disorder (292) 300.12 (F44.0) Dissociative Amnesia (298) Specify if: 300.13 (F44.1) With dissociative fugue 300.6 (F48.1) Depersonalization/Derealization Disorder (302) 300.15 (F44.89) Other Specified Dissociative Disorder (306) 300.15 (F44.9) Unspecified Dissocia tive Disorder (307) Somatic Symptom and Related Disorders (309) 300.82 (F45.1) Somatic Symptom Disorder (311) Specify if: With predominant pain Specify if: Persistent Specify current severity: Mild, Moderate, Severe 300.7 (F45.21) Illness Anxiety Disorder (315) Specify whether: Care seeking type, Care avoidant type
dsm5.pdf
a829f62eda84-1
Specify whether: Care seeking type, Care avoidant type 300.11 (___.__) Conversion Disorder (Functional Neurological Symptom Disorder) (318) Specify symptom type: (F44.4) With weakness or paralysis (F44.4) With abnormal movement (F44.4) With swallowing symptoms (F44.4) With speech symptom (F44.5) With attacks or seizures (F44.6) With anesthesia or sensory loss (F44.6) With special sensory symptom (F44.7) With mixed symptoms Specify if: Acute episode, Persistent Specify if: With psychological stressor (s pecify stressor), Without psycho- logical stressor
dsm5.pdf
22d0388ebb9e-0
DSM-5 Classification xxi 316 (F54) Psychological Factors Affecting Other Medical Conditions (322) Specify current severity: Mild, Moderate, Severe, Extreme 300.19 (F68.10) Factitious Disorder (includes Fact itious Disorder Imposed on Self, Factitious Disorder Imposed on Another) (324) Specify Single episode, Recurrent episodes 300.89 (F45.8) Other Specified Somatic Symptom and Related Disorder (327) 300.82 (F45.9) Unspecified Somatic Symptom and Related Disorder (327) Feeding and Eating Disorders (329) The following specifiers apply to Feedin g and Eating Disorders where indicated: aSpecify if: In remission bSpecify if: In partial remission, In full remission cSpecify current severity: Mild, Moderate, Severe, Extreme 307.52 (___.__) Picaa (329) (F98.3) In children (F50.8) In adults 307.53 (F98.21) Rumination Disordera (332) 307.59 (F50.8) Avoidant/Restrictive Food Intake Disordera (334) 307.1 (___.__) Anorexia Nervosab, c (338) Specify whether: (F50.01) Restricting type (F50.02) Binge-eating/purging type 307.51 (F50.2) Bulimia Nervosab, c (345) 307.51 (F50.8) Binge-Eating Disorderb, c (350) 307.59 (F50.8) Other Specified Feeding or Eating Disorder (353)
dsm5.pdf
22d0388ebb9e-1
307.50 (F50.9) Unspecified Feeding or Eating Disorder (354) Elimination Disorders (355) 307.6 (F98.0) Enuresis (355) Specify whether: Nocturnal only, Diur nal only, Nocturnal and diurnal 307.7 (F98.1) Encopresis (357) Specify whether: With constipation an d overflow incontinence, Without constipation and overflow incontinence ___.__ (___.__) Other Specified Elimination Disorder (359) 788.39 (N39.498) With urinary symptoms 787.60 (R15.9) With fecal symptoms ___.__ (___.__) Unspecified Elimination Disorder (360) 788.30 (R32) With urinary symptoms 787.60 (R15.9) With fecal symptoms
dsm5.pdf
539821d96d12-0
xxii DSM-5 Classification Sleep-Wake Disorders (361) The following specifiers apply to Sl eep-Wake Disorders where indicated: aSpecify if: Episodic, Persistent, Recurrent bSpecify if: Acute, Subacute, Persistent cSpecify current severity: Mi ld, Moderate, Severe 307.42 (F51.01) Insomnia Disordera (362) Specify if: With non–sleep disorder mental comorbidity, With other medical comorbidity, With other sleep disorder 307.44 (F51.11) Hypersomnolence Disorderb, c (368) Specify if: With mental disorder, With medical condition, With another sleep disorder ___.__ (___.__) Narcolepsyc (372) Specify whether: 347.00 (G47.419) Narcolepsy without cataplexy bu t with hypocretin deficiency 347.01 (G47.411) Narcolepsy with cataplexy but without hypocretin deficiency 347.00 (G47.419) Autosomal dominant cerebellar ataxia, deafness, and narcolepsy 347.00 (G47.419) Autosomal dominant narcolepsy, obesity, and type 2 diabetes 347.10 (G47.429) Narcolepsy secondary to another medical condition Breathing-Related Sleep Disorders (378) 327.23 (G47.33) Obstructive Sleep Apnea Hypopneac (378) ___.__ (___.__) Central Sleep Apnea (383) Specify whether: 327.21 (G47.31) Idiopathic central sleep apnea 786.04 (R06.3) Cheyne-Stokes breathing
dsm5.pdf
539821d96d12-1
786.04 (R06.3) Cheyne-Stokes breathing 780.57 (G47.37) Central sleep apnea comorbid with opioid use Note: First code opioid use disorder, if present. Specify current severity ___.__ (___.__) Sleep-Related Hypoventilation (387) Specify whether: 327.24 (G47.34) Idiopathic hypoventilation 327.25 (G47.35) Congenital central alve olar hypoventilation 327.26 (G47.36) Comorbid sleep-related hypoventilation Specify current severity ___.__ (___.__) Circadian Rhythm Sleep-Wake Disordersa (390) Specify whether: 307.45 (G47.21) Delayed sleep phase type (391) Specify if: Familial, Overlapping with non-24-hour sleep-wake type 307.45 (G47.22) Advanced sleep phase type (393) Specify if: Familial 307.45 (G47.23) Irregular sleep-wake type (394) 307.45 (G47.24) Non-24-hour sleep-wake type (396)
dsm5.pdf
98c9e33f87f0-0
DSM-5 Classification xxiii 307.45 (G47.26) Shift work type (397) 307.45 (G47.20) Unspecified type Parasomnias (399) ___.__ (__.__) Non–Rapid Eye Movement Sleep Arousal Disorders (399) Specify whether: 307.46 (F51.3) Sleepwalking type Specify if: With sleep-related eating , With sleep-related sexual behavior (sexsomnia) 307.46 (F51.4) Sleep terror type 307.47 (F51.5) Nightmare Disorderb, c (404) Specify if: During sleep onset Specify if: With associated non–sleep disorder, With associated other medical condition, With associated other sleep disorder 327.42 (G47.52) Rapid Eye Movement Sleep Behavior Disorder (407) 333.94 (G25.81) Restless Legs Syndrome (410) ___.__ (___.__) Substance/Medication-Induc ed Sleep Disorder (413) Note: See the criteria set and corresponding recording procedures for substance-specific codes and ICD-9-CM and ICD-10-CM coding. Specify whether: Insomnia type, Dayt ime sleepiness type, Parasomnia type, Mixed type Specify if: With onset during intoxicatio n, With onset during discontinua- tion/withdrawal 780.52 (G47.09) Other Specified Insomnia Disorder (420) 780.52 (G47.00) Unspecified Insomnia Disorder (420) 780.54 (G47.19) Other Specified Hypersomnolence Disorder (421) 780.54 (G47.10) Unspecified Hypersomnolence Disorder (421)
dsm5.pdf
98c9e33f87f0-1
780.59 (G47.8) Other Specified Sleep-Wake Disorder (421) 780.59 (G47.9) Unspecified Sleep-Wake Disorder (422) Sexual Dysfunctions (423) The following specifiers apply to Sexual Dysfunctions where indicated: aSpecify whether: Lifelong, Acquired bSpecify whether: Generalized, Situational cSpecify current severity: Mi ld, Moderate, Severe 302.74 (F52.32) Delayed Ejaculationa, b, c (424) 302.72 (F52.21) Erectile Disordera, b, c (426) 302.73 (F52.31) Female Orgasmic Disordera, b, c (429) Specify if: Never experienced an orgasm under any situation 302.72 (F52.22) Female Sexual Interest/Arousal Disordera, b, c (433) 302.76 (F52.6) Genito-Pelvic Pain/Penetration Disordera, c (437)
dsm5.pdf
fe90bf07c27e-0
xxiv DSM-5 Classification 302.71 (F52.0) Male Hypoactive Sexual Desire Disordera, b, c (440) 302.75 (F52.4) Premature (Early) Ejaculationa, b, c (443) ___.__ (___.__) Substance/Medication-Induc ed Sexual Dysfunctionc (446) Note: See the criteria set and corresponding recording procedures for substance-specific codes and IC D-9-CM and ICD-10-CM coding. Specify if: With onset during intoxicatio n, With onset during withdrawal, With onset after medication use 302.79 (F52.8) Other Specified Sexual Dysfunction (450) 302.70 (F52.9) Unspecified Sexual Dysfunction (450) Gender Dysphoria (451) ___.__ (__.__) Gender Dysphoria (452) 302.6 (F64.2) Gender Dysphoria in Children Specify if: With a disorder of sex development 302.85 (F64.1) Gender Dysphoria in Adolescents and Adults Specify if: With a disorder of sex development Specify if: Posttransition Note: Code the disorder of sex develo pment if present, in addition to gender dysphoria. 302.6 (F64.8) Other Specified Gender Dysphoria (459) 302.6 (F64.9) Unspecified Gender Dysphoria (459) Disruptive, Impulse-Contro l, and Conduct Disorders (461) 313.81 (F91.3) Oppositional Defi ant Disorder (462) Specify current severity: Mild, Moderate, Severe
dsm5.pdf
fe90bf07c27e-1
Specify current severity: Mild, Moderate, Severe 312.34 (F63.81) Intermittent Explosive Disorder (466) ___.__ (__.__) Conduct Disorder (469) Specify whether: 312.81 (F91.1) Childhood-onset type 312.82 (F91.2) Adolescent-onset type 312.89 (F91.9) Unspecified onset Specify if: With limited prosocial emotions Specify current severity: Mild, Moderate, Severe 301.7 (F60.2) Antisocial Personality Disorder (476) 312.33 (F63.1) Pyromania (476) 312.32 (F63.2) Kleptomania (478) 312.89 (F91.8) Other Specified Disruptive, Impulse-Control, and Conduct Disorder (479) 312.9 (F91.9) Unspecified Disruptive, Impulse-Control, and Conduct Disorder (480)
dsm5.pdf
fee7ba06bff9-0
DSM-5 Classification xxv Substance-Related and Addictive Disorders (481) The following specifiers and note apply to Substance-Related and Addictive Disorders where indicated: aSpecify if: In early remission, In sustained remission bSpecify if: In a controlled environment cSpecify if: With perceptual disturbances dThe ICD-10-CM code indicates the comorbid pres ence of a moderate or severe substance use disorder, which must be present in order to apply the code for substance withdrawal. Substance-Related Disorders (483) Alcohol-Related Disorders (490) ___.__ (___.__) Alcohol Use Disordera, b (490) Specify current severity: 305.00 (F10.10) Mild 303.90 (F10.20) Moderate 303.90 (F10.20) Severe 303.00 (___.__) Alcohol Intoxi cation (497) (F10.129) With use disorder, mild (F10.229) With use disorder, moderate or severe (F10.929) Without use disorder 291.81 (___.__) Alcohol Withdrawalc, d (499) (F10.239) Without perceptual disturbances (F10.232) With perceptual disturbances ___.__ (___.__) Other Alcohol-Induced Disorders (502) 291.9 (F10.99) Unspecified Alcohol-Related Disorder (503) Caffeine-Related Disorders (503) 305.90 (F15.929) Caffeine Intoxication (503) 292.0 (F15.93) Caffeine Withdrawal (506) ___.__ (___.__) Other Caffeine-Induc ed Disorders (508)
dsm5.pdf
fee7ba06bff9-1
___.__ (___.__) Other Caffeine-Induc ed Disorders (508) 292.9 (F15.99) Unspecified Caffeine-Related Disorder (509) Cannabis-Related Disorders (509) ___.__ (___.__) Cannabis Use Disordera, b (509) Specify current severity: 305.20 (F12.10) Mild 304.30 (F12.20) Moderate 304.30 (F12.20) Severe
dsm5.pdf
9bf6239863ce-0
xxvi DSM-5 Classification 292.89 (___.__) Cannabis Intoxicationc (516) Without perceptual disturbances (F12.129) With use disorder, mild (F12.229) With use disorder, moderate or severe (F12.929) Without use disorder With perceptual disturbances (F12.122) With use disorder, mild (F12.222) With use disorder, moderate or severe (F12.922) Without use disorder 292.0 (F12.288) Cannabis Withdrawald (517) ___.__ (___.__) Other Cannabis-Induced Disorders (519) 292.9 (F12.99) Unspecified Cannabis-Related Disorder (519) Hallucinogen-Related Disorders (520) ___.__ (___.__) Phencyclidine Use Disordera, b (520) Specify current severity: 305.90 (F16.10) Mild 304.60 (F16.20) Moderate 304.60 (F16.20) Severe ___.__ (___.__) Other Hallucinogen Use Disordera, b (523) Specify the particular hallucinogen Specify current severity: 305.30 (F16.10) Mild 304.50 (F16.20) Moderate 304.50 (F16.20) Severe 292.89 (___.__) Phencyclidine Intoxication (527) (F16.129) With use disorder, mild (F16.229) With use disorder, moderate or severe (F16.929) Without use disorder 292.89 (___.__) Other Hallucinogen Intoxication (529) (F16.129) With use disorder, mild (F16.229) With use disorder, moderate or severe
dsm5.pdf
9bf6239863ce-1
(F16.229) With use disorder, moderate or severe (F16.929) Without use disorder 292.89 (F16.983) Hallucinogen Persisting Pe rception Disorder (531) ___.__ (___.__) Other Phencyclidine-Induced Disorders (532) ___.__ (___.__) Other Hallucinogen-Induced Disorders (532) 292.9 (F16.99) Unspecified Phencyclidine-Related Disorder (533) 292.9 (F16.99) Unspecified Hallucinogen-R elated Disorder (533) Inhalant-Related Disorders (533) ___.__ (___.__) Inhalant Use Disordera, b (533) Specify the particular inhalant Specify current severity: 305.90 (F18.10) Mild
dsm5.pdf
8d34144e671d-0
DSM-5 Classification xxvii 304.60 (F18.20) Moderate 304.60 (F18.20) Severe 292.89 (___.__) Inhalant Intoxication (538) (F18.129) With use disorder, mild (F18.229) With use disorder, moderate or severe (F18.929) Without use disorder ___.__ (___.__) Other Inhalant-Induced Disorders (540) 292.9 (F18.99) Unspecified Inhalant-Related Disorder (540) Opioid-Related Disorders (540) ___.__ (___.__) Opioid Use Disordera (541) Specify if: On maintenance therapy, In a controlled environment Specify current severity: 305.50 (F11.10) Mild 304.00 (F11.20) Moderate 304.00 (F11.20) Severe 292.89 (___.__) Opioid Intoxicationc (546) Without perceptual disturbances (F11.129) With use disorder, mild (F11.229) With use disorder, moderate or severe (F11.929) Without use disorder With perceptual disturbances (F11.122) With use disorder, mild (F11.222) With use disorder, moderate or severe (F11.922) Without use disorder 292.0 (F11.23) Opioid Withdrawald (547) ___.__ (___.__) Other Opioid-Induced Disorders (549) 292.9 (F11.99) Unspecified Opioid-Related Disorder (550) Sedative-, Hypnotic-, or Anxiolytic-Related Disorders (550)
dsm5.pdf
8d34144e671d-1
Sedative-, Hypnotic-, or Anxiolytic-Related Disorders (550) ___.__ (___.__) Sedative, Hypnotic, or Anxiolytic Use Disordera, b (550) Specify current severity: 305.40 (F13.10) Mild 304.10 (F13.20) Moderate 304.10 (F13.20) Severe 292.89 (___.__) Sedative, Hypnotic, or Anxi olytic Intoxication (556) (F13.129) With use disorder, mild (F13.229) With use disorder, moderate or severe (F13.929) Without use disorder 292.0 (___.__) Sedative, Hypnotic, or Anxiolytic Withdrawalc, d (557) (F13.239) Without perceptual disturbances (F13.232) With perceptual disturbances
dsm5.pdf
759d006edab3-0
xxviii DSM-5 Classification ___.__ (___.__) Other Sedative-, Hypnotic-, or Anxiolytic-Induced Disorders (560) 292.9 (F13.99) Unspecified Sedative-, Hypnotic-, or Anxiolytic-Related Disorder (560) Stimulant-Related Disorders (561) ___.__ (___.__) Stimulant Use Disordera, b (561) Specify current severity: ___.__ (___.__) Mild 305.70 (F15.10) Amphetamine-type substance 305.60 (F14.10) Cocaine 305.70 (F15.10) Other or unspecified stimulant ___.__ (___.__) Moderate 304.40 (F15.20) Amphetamine-type substance 304.20 (F14.20) Cocaine 304.40 (F15.20) Other or unspecified stimulant ___.__ (___.__) Severe 304.40 (F15.20) Amphetamine-type substance 304.20 (F14.20) Cocaine 304.40 (F15.20) Other or unspecified stimulant 292.89 (___.__) Stimulant Intoxicationc (567) Specify the specific intoxicant 292.89 (___.__) Amphetamine or other stimulant, Without perceptual disturbances (F15.129) With use disorder, mild (F15.229) With use disorder, moderate or severe (F15.929) Without use disorder 292.89 (___.__) Cocaine, Without perceptual disturbances (F14.129) With use disorder, mild (F14.229) With use disorder, moderate or severe (F14.929) Without use disorder
dsm5.pdf
759d006edab3-1
(F14.929) Without use disorder 292.89 (___.__) Amphetamine or other stimulant, With perceptual disturbances (F15.122) With use disorder, mild (F15.222) With use disorder, moderate or severe (F15.922) Without use disorder 292.89 (___.__) Cocaine, With perceptual disturbances (F14.122) With use disorder, mild (F14.222) With use disorder, moderate or severe (F14.922) Without use disorder 292.0 (___.__) Stimulant Withdrawald (569) Specify the specific substance causing the withdrawal syndrome (F15.23) Amphetamine or other stimulant (F14.23) Cocaine ___.__ (___.__) Other Stimulant-Induced Disorders (570)
dsm5.pdf
c9df4f365e78-0
DSM-5 Classification xxix 292.9 (___.__) Unspecified Stimulant-Related Disorder (570) (F15.99) Amphetamine or other stimulant (F14.99) Cocaine Tobacco-Related Disorders (571) ___.__ (___.__) Tobacco Use Disordera (571) Specify if: On maintenance therapy, In a controlled environment Specify current severity: 305.1 (Z72.0) Mild 305.1 (F17.200) Moderate 305.1 (F17.200) Severe 292.0 (F17.203) Tobacco Withdrawald (575) ___.__ (___.__) Other Tobacco-Induced Disorders (576) 292.9 (F17.209) Unspecified Tobacco-Related Disorder (577) Other (or Unknown) Substance–Related Disorders (577) ___._ (___.__) Other (or Unknown) Substance Use Disordera, b (577) Specify current severity: 305.90 (F19.10) Mild 304.90 (F19.20) Moderate 304.90 (F19.20) Severe 292.89 (___.__) Other (or Unknown) Substance Intoxication (581) (F19.129) With use disorder, mild (F19.229) With use disorder, moderate or severe (F19.929) Without use disorder 292.0 (F19.239) Other (or Unknown) Substance Withdrawald (583) ___.__ (___.__) Other (or Unknown) Substance–Induced Disorders (584) 292.9 (F19.99) Unspecified Other (or Unknown) Su bstance–Related Disorder (585) Non-Substance-Related Disorders (585)
dsm5.pdf
c9df4f365e78-1
Non-Substance-Related Disorders (585) 312.31 (F63.0) Gambling Disordera (585) Specify if: Episodic, Persistent Specify current severity: Mild, Moderate, Severe Neurocognitive Disorders (591) ___.__ (___.__) Delirium (596) aNote: See the criteria set and corresponding recording procedures for substance-specific codes and ICD-9-CM and ICD-10-CM coding. Specify whether: ___.__ (___.__) Substance intoxication deliriuma ___.__ (___.__) Substance withdrawal deliriuma 292.81 (___.__) Medication-induced deliriuma 293.0 (F05) Delirium due to another medical condition
dsm5.pdf
ba5a0451f257-0
xxx DSM-5 Classification 293.0 (F05) Delirium due to multiple etiologies Specify if: Acute, Persistent Specify if: Hyperactive, Hypoacti ve, Mixed level of activity 780.09 (R41.0) Other Specified Delirium (602) 780.09 (R41.0) Unspecified Delirium (602) Major and Mild Neurocognitive Disorders (602) Specify whether due to: Alzheimer’s disease, Frontotemporal lobar degeneration, Lewy body disease, Vascular disease, Traumatic brain injury, Substance/medication use, HIV infection, Prion disease, Parkinson’s disease, Huntington’s disease, Another medical condition, Multi- ple etiologies, Unspecified aSpecify Without behavioral disturbance, With behavioral disturbance. For possible major neuro- cognitive disorder and for mild ne urocognitive disorder, behavioral disturbanc e cannot be coded but should still be indicated in writing. bSpecify current severity: Mild, Moderate, Severe. This specifier applies only to major neurocogni- tive disorders (i ncluding probable and possible). Note: As indicated for each subtype, an additional medical code is needed for probable major neurocognitive disorder or majo r neurocognitive disorder. An additional medical code should not be used for possible major neurocognitive disorder or mild neur ocognitive disorder. Major or Mild Neurocognitive Disorder Due to Alzheimer’s Disease (611) ___.__ (___.__) Probable Major Neurocognitive Disorder Due to Alzheimer’s Diseaseb Note: Code first 331.0 (G30.9) Alzheimer’s disease. 294.11 (F02.81) With behavioral disturbance
dsm5.pdf
ba5a0451f257-1
294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.9 (G31.9) Possible Major Neurocognitive Disorder Due to Alzheimer’s Diseasea, b 331.83 (G31.84) Mild Neurocognitive Disorder Due to Alzheimer’s Diseasea Major or Mild Frontotemporal Neurocognitive Disorder (614) ___.__ (___.__) Probable Major Neurocognitive Di sorder Due to Frontotemporal Lobar Degenerationb Note: Code first 331.19 (G31.09) frontotemporal disease. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.9 (G31.9) Possible Major Neurocognitive Disorder Due to Frontotemporal Lobar Degenerationa, b 331.83 (G31.84) Mild Neurocognitive Disorder Due to Frontotemporal Lobar Degenerationa Major or Mild Neurocognitive Disorder With Lewy Bodies (618) ___.__ (___.__) Probable Major Neurocognitive Disorder With Lewy Bodiesb Note: Code first 331.82 (G31.83) Lewy body disease. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance
dsm5.pdf
d79501ac5e3f-0
DSM-5 Classification xxxi 331.9 (G31.9) Possible Major Neurocognitive Disorder With Lewy Bodiesa, b 331.83 (G31.84) Mild Neurocognitive Disorder With Lewy Bodiesa Major or Mild Vascular Neurocognitive Disorder (621) ___.__ (___.__) Probable Major Vascular Neurocognitive Disorderb Note: No additional medical code for vascular disease. 290.40 (F01.51) With behavioral disturbance 290.40 (F01.50) Without behavioral disturbance 331.9 (G31.9) Possible Major Vascular Neurocognitive Disordera, b 331.83 (G31.84) Mild Vascular Neur ocognitive Disordera Major or Mild Neurocognitive Disorder Due to Traumatic Brain Injury (624) ___.__ (___.__) Major Neurocognitive Disorder Due to Traumatic Brain Injuryb Note: For ICD-9-CM, code first 907.0 late effect of intracranial injury without skull fracture. For IC D-10-CM, code first S06.2X9S diffuse traumatic brain injury with loss of consciousness of unspecified duration, sequela. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.83 (G31.84) Mild Neurocognitive Disorder Due to Traumatic Brain Injurya Substance/Medication-Induced Major or Mild Neurocognitive Disordera (627) Note: No additional medical code. See the criter ia set and corresponding recording procedures for substance-specific codes and ICD-9-CM and ICD-10-CM coding. Specify if: Persistent
dsm5.pdf
d79501ac5e3f-1
Specify if: Persistent Major or Mild Neurocognitive Disorder Due to HIV Infection (632) ___.__ (___.__) Major Neurocognitive Disorder Due to HIV Infectionb Note: Code first 042 (B20) HIV infection. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.83 (G31.84) Mild Neurocognitive Disorder Due to HIV Infectiona Major or Mild Neurocognitive Disorder Due to Prion Disease (634) ___.__ (___.__) Major Neurocognitive Disord er Due to Prion Diseaseb Note: Code first 046.79 (A81.9) prion disease. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.83 (G31.84) Mild Neurocognitive Disorder Due to Prion Diseasea Major or Mild Neurocognitive Disorder Due to Parkinson’s Disease (636) ___.__ (___.__) Major Neurocognitive Disorder Probably Due to Parkinson’s Diseaseb Note: Code first 332.0 (G20) Parkinson’s disease. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance
dsm5.pdf
b242bdd7d8d4-0
xxxii DSM-5 Classification 331.9 (G31.9) Major Neurocognitive Disorder Possibly Due to Parkinson’s Diseasea, b 331.83 (G31.84) Mild Neurocognitive Disorder Due to Parkinson’s Diseasea Major or Mild Neurocognitive Disorder Due to Huntington’s Disease (638) ___.__ (___.__) Major Neurocognitive Disorder Due to Huntington’s Diseaseb Note: Code first 333.4 (G10) Huntington’s disease. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.83 (G31.84) Mild Neurocognitive Disorder Due to Huntington’s Diseasea Major or Mild Neurocognitive Disorder Due to Another Medical Condition (641) ___.__ (___.__) Major Neurocognitive Disord er Due to Another Medical Conditionb Note: Code first the other medical condition. 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.83 (G31.84) Mild Neurocognitive Disorder Due to Another Medical Conditiona Major or Mild Neurocognitive Disorder Due to Multiple Etiologies (642) ___.__ (___.__) Major Neurocognitive Disorder Due to Multiple Etiologiesb Note: Code first all the etiological medical conditions (with the exception of vascular disease). 294.11 (F02.81) With behavioral disturbance 294.10 (F02.80) Without behavioral disturbance 331.83 (G31.84) Mild Neurocognitive Disorder Due to Multiple Etiologiesa Unspecified Neurocognit ive Disorder (643)
dsm5.pdf
b242bdd7d8d4-1
Unspecified Neurocognit ive Disorder (643) 799.59 (R41.9) Unspecified Neurocognitive Disordera Personality Disorders (645) Cluster A Personality Disorders 301.0 (F60.0) Paranoid Personality Disorder (649) 301.20 (F60.1) Schizoid Personality Disorder (652) 301.22 (F21) Schizotypal Personality Disorder (655) Cluster B Personality Disorders 301.7 (F60.2) Antisocial Personality Disorder (659) 301.83 (F60.3) Borderline Personality Disorder (663) 301.50 (F60.4) Histrionic Personality Disorder (667) 301.81 (F60.81) Narcissistic Personality Disorder (669)
dsm5.pdf
df9dfe94c6b9-0
DSM-5 Classification xxxiii Cluster C Personality Disorders 301.82 (F60.6) Avoidant Personality Disorder (672) 301.6 (F60.7) Dependent Personalit y Disorder (675) 301.4 (F60.5) Obsessive-Compulsive Personality Disorder (678) Other Personality Disorders 310.1 (F07.0) Personality Change Due to Another Medical Condition (682) Specify whether: Labile type, Disinhibited type, Aggressive type, Apathetic type, Paranoid type, Other type, Combined type, Unspecified type 301.89 (F60.89) Other Specified Personality Disorder (684) 301.9 (F60.9) Unspecified Personality Disorder (684) Paraphilic Disorders (685) The following specifier applies to Pa raphilic Disorders where indicated: aSpecify if: In a controlled environment, In full remission 302.82 (F65.3) Voyeuristic Disordera (686) 302.4 (F65.2) Exhibitionistic Disordera (689) Specify whether: Sexually aroused by exposing genitals to prepubertal children, Sexually aroused by exposi ng genitals to physically mature individuals, Sexually aroused by exposing genitals to prepubertal chil- dren and to physically mature individuals 302.89 (F65.81) Frotteuristic Disordera (691) 302.83 (F65.51) Sexual Masochism Disordera (694) Specify if: With asphyxiophilia 302.84 (F65.52) Sexual Sadism Disordera (695) 302.2 (F65.4) Pedophilic Disorder (697)
dsm5.pdf
df9dfe94c6b9-1
302.2 (F65.4) Pedophilic Disorder (697) Specify whether: Exclusive type, Nonexclusive type Specify if: Sexually attracted to males, Se xually attracted to females, Sexu- ally attracted to both Specify if: Limited to incest 302.81 (F65.0) Fetishistic Disordera (700) Specify: Body part(s), Nonliving object(s), Other 302.3 (F65.1) Transvestic Disordera (702) Specify if: With fetishism, With autogynephilia 302.89 (F65.89) Other Specified Paraphilic Disorder (705) 302.9 (F65.9) Unspecified Paraphilic Disorder (705) Other Mental Disorders (707) 294.8 (F06.8) Other Specified Mental Disorder Due to Another Medical Condition (707) 294.9 (F09) Unspecified Mental Disorder Due to Another Medical Condition (708) 300.9 (F99) Other Specified Mental Disorder (708) 300.9 (F99) Unspecified Mental Disorder (708)
dsm5.pdf
40d97c1e5546-0
xxxiv DSM-5 Classification Medication-Induced Movement Disorders and Other Adverse Effects of Medication (709) 332.1 (G21.11) Neuroleptic-Induced Parkinsonism (709) 332.1 (G21.19) Other Medication-Induced Parkinsonism (709) 333.92 (G21.0) Neuroleptic Malignant Syndrome (709) 333.72 (G24.02) Medication-Induced Acute Dystonia (711) 333.99 (G25.71) Medication-Induced Acute Akathisia (711) 333.85 (G24.01) Tardive Dyskinesia (712) 333.72 (G24.09) Tardive Dystonia (712) 333.99 (G25.71) Tardive Akathisia (712) 333.1 (G25.1) Medication-Induced Postural Tremor (712) 333.99 (G25.79) Other Medication-Induced Movement Disorder (712) ___.__ (___.__) Antidepressant Disconti nuation Syndrome (712) 995.29 (T43.205A) Initial encounter 995.29 (T43.205D) Subsequent encounter 995.29 (T43.205S) Sequelae ___.__ (___.__) Other Adverse Effect of Medication (714) 995.20 (T50.905A) Initial encounter 995.20 (T50.905D) Subsequent encounter 995.20 (T50.905S) Sequelae Other Conditions That May Be a Focus of Clinical Attention (715) Relational Problems (715)
dsm5.pdf
40d97c1e5546-1
of Clinical Attention (715) Relational Problems (715) Problems Related to Fa mily Upbringing (715) V61.20 (Z62.820) Parent-Child Relational Problem (715) V61.8 (Z62.891) Sibling Relational Problem (716) V61.8 (Z62.29) Upbringing Away From Parents (716) V61.29 (Z62.898) Child Affected by Parental Relationship Distress (716) Other Problems Related to Primary Support Group (716) V61.10 (Z63.0) Relationship Distress With Spouse or Intimate Partner (716) V61.03 (Z63.5) Disruption of Family by Se paration or Divorce (716) V61.8 (Z63.8) High Expressed Emotion Level Within Family (716) V62.82 (Z63.4) Uncomplicated Bereavement (716)
dsm5.pdf
3d061eda7bc2-0
DSM-5 Classification xxxv Abuse and Neglect (717) Child Maltreatment and Neglect Problems (717) Child Physical Abuse (717) Child Physical Abuse, Confirmed (717) 995.54 (T74.12XA) Initial encounter 995.54 (T74.12XD) Subsequent encounter Child Physical Abuse, Suspected (717) 995.54 (T76.12XA) Initial encounter 995.54 (T76.12XD) Subsequent encounter Other Circumstances Related to Child Physical Abuse (718) V61.21 (Z69.010) Encounter for mental health serv ices for victim of child abuse by parent V61.21 (Z69.020) Encounter for mental health services for victim of nonparental child abuse V15.41 (Z62.810) Personal history (past history) of physical abuse in childhood V61.22 (Z69.011) Encounter for mental health services for perpetrator of parental child abuse V62.83 (Z69.021) Encounter for mental health services for perpetrator of nonparental child abuse Child Sexual Abuse (718) Child Sexual Abuse, Confirmed (718) 995.53 (T74.22XA) Initial encounter 995.53 (T74.22XD) Subsequent encounter Child Sexual Abuse, Suspected (718) 995.53 (T76.22XA) Initial encounter 995.53 (T76.22XD) Subsequent encounter Other Circumstances Related to Child Sexual Abuse (718) V61.21 (Z69.010) Encounter for mental health services for victim of child sexual abuse by parent
dsm5.pdf
3d061eda7bc2-1
abuse by parent V61.21 (Z69.020) Encounter for mental health services for victim of nonparental child sexual abuse V15.41 (Z62.810) Personal history (past history) of sexual abuse in childhood V61.22 (Z69.011) Encounter for mental health services for perpetrator of parental child sexual abuse V62.83 (Z69.021) Encounter for mental health services for perpetrator of nonparental child sexual abuse Child Neglect (718) Child Neglect, Confirmed (718) 995.52 (T74.02XA) Initial encounter 995.52 (T74.02XD) Subsequent encounter
dsm5.pdf
bbbac78fd743-0
xxxvi DSM-5 Classification Child Neglect, Suspected (719) 995.52 (T76.02XA) Initial encounter 995.52 (T76.02XD) Subsequent encounter Other Circumstances Related to Child Neglect (719) V61.21 (Z69.010) Encounter for mental health services for victim of child neglect by parent V61.21 (Z69.020) Encounter for mental health services for victim of nonparental child neglect V15.42 (Z62.812) Personal history (past histor y) of neglect in childhood V61.22 (Z69.011) Encounter for mental health services for perpetrator of parental child neglect V62.83 (Z69.021) Encounter for mental health services for perpetrator of nonparental child neglect Child Psychological Abuse (719) Child Psychological Abuse, Confirmed (719) 995.51 (T74.32XA) Initial encounter 995.51 (T74.32XD) Subsequent encounter Child Psychological Abuse, Suspected (719) 995.51 (T76.32XA) Initial encounter 995.51 (T76.32XD) Subsequent encounter Other Circumstances Related to Child Psychological Abuse (719) V61.21 (Z69.010) Encounter for mental health se rvices for victim of child psychological abuse by parent V61.21 (Z69.020) Encounter for mental health services for victim of nonparental child psychological abuse V15.42 (Z62.811) Personal history (past history) of psychological abuse in childhood V61.22 (Z69.011) Encounter for mental health services for perpetrator of parental child psychological abuse
dsm5.pdf
bbbac78fd743-1
child psychological abuse V62.83 (Z69.021) Encounter for mental health services for perpetrator of nonparental child psychological abuse Adult Maltreatment and Neglect Problems (720) Spouse or Partner Violence, Physical (720) Spouse or Partner Violence, Physical, Confirmed (720) 995.81 (T74.11XA) Initial encounter 995.81 (T74.11XD) Subsequent encounter Spouse or Partner Violence, Physical, Suspected (720) 995.81 (T76.11XA) Initial encounter 995.81 (T76.11XD) Subsequent encounter Other Circumstances Related to Spouse or Partner Violence, Physical (720) V61.11 (Z69.11) Encounter for mental health serv ices for victim of spouse or partner violence, physical
dsm5.pdf
bd7aa62861e6-0
DSM-5 Classification xxxvii V15.41 (Z91.410) Personal history (past history) of spouse or partner violence, physical V61.12 (Z69.12) Encounter for mental health serv ices for perpetrator of spouse or partner violence, physical Spouse or Partner Violence, Sexual (720) Spouse or Partner Violence, Sexual, Confirmed (720) 995.83 (T74.21XA) Initial encounter 995.83 (T74.21XD) Subsequent encounter Spouse or Partner Violence, Sexual, Suspected (720) 995.83 (T76.21XA) Initial encounter 995.83 (T76.21XD) Subsequent encounter Other Circumstances Related to Spouse or Partner Violence, Sexual (720) V61.11 (Z69.81) Encounter for mental health serv ices for victim of spouse or partner violence, sexual V15.41 (Z91.410) Personal history (past history) of spouse or partner violence, sexual V61.12 (Z69.12) Encounter for mental health serv ices for perpetrator of spouse or partner violence, sexual Spouse or Partner, Neglect (721) Spouse or Partner Neglect, Confirmed (721) 995.85 (T74.01XA) Initial encounter 995.85 (T74.01XD) Subsequent encounter Spouse or Partner Neglect, Suspected (721) 995.85 (T76.01XA) Initial encounter 995.85 (T76.01XD) Subsequent encounter Other Circumstances Related to Spouse or Partner Neglect (721)
dsm5.pdf
bd7aa62861e6-1
Other Circumstances Related to Spouse or Partner Neglect (721) V61.11 (Z69.11) Encounter for mental health serv ices for victim of spouse or partner neglect V15.42 (Z91.412) Personal history (past history) of spouse or partner neglect V61.12 (Z69.12) Encounter for mental health serv ices for perpetrator of spouse or partner neglect Spouse or Partner Abuse, Psychological (721) Spouse or Partner Abuse, Psychological, Confirmed (721) 995.82 (T74.31XA) Initial encounter 995.82 (T74.31XD) Subsequent encounter Spouse or Partner Abuse, Psychological, Suspected (721) 995.82 (T76.31XA) Initial encounter 995.82 (T76.31XD) Subsequent encounter Other Circumstances Related to Spouse or Partner Abuse, Psychological (721) V61.11 (Z69.11) Encounter for mental health serv ices for victim of spouse or partner psychological abuse
dsm5.pdf
2ee3a96eefeb-0
xxxviii DSM-5 Classification V15.42 (Z91.411) Personal history (past history) of spouse or partner psychological abuse V61.12 (Z69.12) Encounter for mental health services for perpetrator of spouse or partner psychological abuse Adult Abuse by Nonspouse or Nonpartner (722) Adult Physical Abuse by Nonspous e or Nonpartner, Confirmed (722) 995.81 (T74.11XA) Initial encounter 995.81 (T74.11XD) Subsequent encounter Adult Physical Abuse by Nonspouse or Nonpartner, Suspected (722) 995.81 (T76.11XA) Initial encounter 995.81 (T76.11XD) Subsequent encounter Adult Sexual Abuse by Nonspouse or Nonpartner, Confirmed (722) 995.83 (T74.21XA) Initial encounter 995.83 (T74.21XD) Subsequent encounter Adult Sexual Abuse by Nonspouse or Nonpartner, Suspected (722) 995.83 (T76.21XA) Initial encounter 995.83 (T76.21XD) Subsequent encounter Adult Psychological Abuse by Nonspo use or Nonpartner, Confirmed (722) 995.82 (T74.31XA) Initial encounter 995.82 (T74.31XD) Subsequent encounter Adult Psychological Abuse by Nonspouse or Nonpartner, Suspected (722) 995.82 (T76.31XA) Initial encounter 995.82 (T76.31XD) Subsequent encounter Other Circumstances Related to Adult Ab use by Nonspouse or Nonpartner (722) V65.49 (Z69.81) Encounter for mental health services for victim of nonspousal
dsm5.pdf
2ee3a96eefeb-1
adult abuse V62.83 (Z69.82) Encounter for mental health services for perpetrator of nonspousal adult abuse Educational and Occupational Problems (723) Educational Problems (723) V62.3 (Z55.9) Academic or Educational Problem (723) Occupational Problems (723) V62.21 (Z56.82) Problem Related to Current Military Deployment Status (723) V62.29 (Z56.9) Other Problem Related to Employment (723) Housing and Economic Problems (723) Housing Problems (723) V60.0 (Z59.0) Homelessness (723) V60.1 (Z59.1) Inadequate Housing (723)
dsm5.pdf
f7a91ceec96a-0
DSM-5 Classification xxxix V60.89 (Z59.2) Discord With Neighbor, Lodger, or Landlord (723) V60.6 (Z59.3) Problem Related to Living in a Residential Institution (724) Economic Problems (724) V60.2 (Z59.4) Lack of Adequate Food or Safe Drinking Water (724) V60.2 (Z59.5) Extreme Poverty (724) V60.2 (Z59.6) Low Income (724) V60.2 (Z59.7) Insufficient Social Insurance or Welfare Support (724) V60.9 (Z59.9) Unspecified Housing or Economic Problem (724) Other Problems Related to the Social Environment (724) V62.89 (Z60.0) Phase of Life Problem (724) V60.3 (Z60.2) Problem Related to Living Alone (724) V62.4 (Z60.3) Acculturation Difficulty (724) V62.4 (Z60.4) Social Exclusion or Rejection (724) V62.4 (Z60.5) Target of (Perceived) Adverse Disc rimination or Persecution (724) V62.9 (Z60.9) Unspecified Problem Related to Social Environment (725) Problems Related to Crime or Interaction With the Legal System (725) V62.89 (Z65.4) Victim of Crime (725) V62.5 (Z65.0) Conviction in Civil or Criminal Proceedings Without Imprisonment (725) V62.5 (Z65.1) Imprisonment or Other Incarceration (725)
dsm5.pdf
f7a91ceec96a-1
V62.5 (Z65.2) Problems Related to Release From Prison (725) V62.5 (Z65.3) Problems Related to Other Legal Circumstances (725) Other Health Service Encounters for Counseling and Medical Advice (725) V65.49 (Z70.9) Sex Counseling (725) V65.40 (Z71.9) Other Counseling or Consultation (725) Problems Related to Other Psychosocial, Personal, and Environmental Circumstances (725) V62.89 (Z65.8) Religious or Spiritual Problem (725) V61.7 (Z64.0) Problems Related to Unwanted Pregnancy (725) V61.5 (Z64.1) Problems Related to Multiparity (725) V62.89 (Z64.4) Discord With Social Service Provider, Including Probation Officer, Case Manager, or So cial Services Worker (725) V62.89 (Z65.4) Victim of Terrorism or Torture (725) V62.22 (Z65.5) Exposure to Disaster, War, or Other Hostilities (725) V62.89 (Z65.8) Other Problem Related to Psyc hosocial Circumstances (725) V62.9 (Z65.9) Unspecified Problem Related to Unspecified Psychosocial Circumstances (725)
dsm5.pdf
0f43c9ecf557-0
xl DSM-5 Classification Other Circumstances of Personal History (726) V15.49 (Z91.49) Other Personal History of Psychological Trauma (726) V15.59 (Z91.5) Personal History of Self-Harm (726) V62.22 (Z91.82) Personal History of Mili tary Deployment (726) V15.89 (Z91.89) Other Personal Risk Factors (726) V69.9 (Z72.9) Problem Related to Lifestyle (726) V71.01 (Z72.811) Adult Antisocial Behavior (726) V71.02 (Z72.810) Child or Adolescent Antisocial Behavior (726) Problems Related to Access to Medical and Other Health Care (726) V63.9 (Z75.3) Unavailability or Inaccessibility of Health Care Facilities (726) V63.8 (Z75.4) Unavailability or Inaccessibility of Other Helping Agencies (726) Nonadherence to Medical Treatment (726) V15.81 (Z91.19) Nonadherence to Medical Treatment (726) 278.00 (E66.9) Overweight or Obesity (726) V65.2 (Z76.5) Malingering (726) V40.31 (Z91.83) Wandering Associated With a Mental Disorder (727) V62.89 (R41.83) Borderline Intellectual Functioning (727)
dsm5.pdf
cba4fc540fe6-0
xliPreface The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM) is a classification of mental di sorders with associ ated criteria de- signed to facilitate more reliable diagnoses of these disorders. With successive editions over the past 60 years, it has become a standard reference for clinical practice in the mental health field. Since a complete description of the underlying pathological processes is not possible for most mental diso rders, it is important to emph asize that the current diagnos- tic criteria are the best available descriptio n of how mental disord ers are expressed and can be recognized by trained clinicians. DSM is intended to serve as a practical, functional, and flexible guide for organizing information that can aid in the accurate diagnosis and treatment of mental disorders. It is a tool for clinicians, an essential educational resource for students and practitioners, and a reference for researchers in the field. Although this edition of DSM was designed fi rst and foremost to be a useful guide to clinical practice, as an official nomenclature it must be applicable in a wide diversity of contexts. DSM has been used by clinicians and researchers from diff erent orientations (bi- ological, psychodynamic, cognitive, behavior al, interpersonal, family/systems), all of whom strive for a common language to commu nicate the essential ch aracteristics of men- tal disorders presented by their patients. The information is of value to all professionals associated with various aspects of mental health care, including psychiatrists, other physicians, psychologists, social workers, nu rses, counselors, forensic and legal special- ists, occupational and rehabilitation therapists , and other health professionals. The criteria are concise and explicit and intended to fac ilitate an objective asse ssment of symptom pre-
dsm5.pdf
cba4fc540fe6-1
sentations in a variety of clinical settings—inpatient, outpatient, partial hospital, consul- tation-liaison, clinical, private practice, an d primary care—as well in general community epidemiological studies of mental disorders. DSM-5 is also a tool for collecting and com- municating accurate public health statistics on mental disorder morbidity and mortality rates. Finally, the criteria and corresponding text serve as a textbook for students early in their profession who need a structured way to understand and diagnose mental disorders as well as for seasoned professionals encounteri ng rare disorders for the first time. Fortu- nately, all of these uses are mutually compatible. These diverse needs and interests were take n into consideration in planning DSM-5. The classification of disorders is harmoniz ed with the World Health Organization’s Inter- national Classification of Diseases (ICD), the official coding system used in the United States, so that the DSM criteria define disorders identified by ICD diagnostic names and code numbers. In DSM-5, both ICD-9-CM and ICD- 10-CM codes (the latter scheduled for adop- tion in October 2014) are attached to the relevant disorders in the classification. Although DSM-5 remains a catego rical classification of sepa rate disorders, we recog- nize that mental disorders do not always fit completely within the boundaries of a single disorder. Some symptom domains, such as de pression and anxiety, involve multiple di- agnostic categories and may reflect common underlying vulnerabilities for a larger group of disorders. In recognition of this reality, the disorders in cluded in DSM-5 were reordered into a revised organizational structure meant to stimulate new clinical perspectives. This new structure corresponds with the organizational arrangement of disorders planned for
dsm5.pdf
cba4fc540fe6-2
new structure corresponds with the organizational arrangement of disorders planned for ICD-11 scheduled for release in 2015. Other enhancements have been introduced to pro- mote ease of use across all settings:
dsm5.pdf
3ad635fe837f-0
xlii Preface •Representation of developmental issues related to diagnosis. The change in chapter organization better reflects a lifespan approach, with disorders more frequently diag- nosed in childhood (e.g., neurodevelopmental disorders) at the beginning of the man- ual and disorders more applicable to olde r adulthood (e.g., neurocognitive disorders) at the end of the manual. Also, within the text, subheadings on development and course provide descriptions of how disorder pr esentations may change across the lifespan. Age-related factors specific to diagnosis (e.g., symptom presentation and prevalence differences in certain age groups) are also included in the text. For added emphasis, these age-related factors have been added to the criteria themselves where applicable (e.g., in the criteria sets for insomnia di sorder and posttraumati c stress disorder, spe- cific criteria describe how symptoms might be expressed in children). Likewise, gender and cultural issues have been integrat ed into the disorders where applicable. •Integration of scientific findings from th e latest research in genetics and neuroimag- ing. The revised chapter structure was informed by recent research in neuroscience and by emerging genetic linkages between diag nostic groups. Genetic and physiological risk factors, prognostic indicators, and so me putative diagnostic markers are high- lighted in the text. This new structure shoul d improve clinicians’ ability to identify di- agnoses in a disorder spectrum based on common neurocircuitry, genetic vulnerability, and environmental exposures. •Consolidation of autistic disorder, Asperg er’s disorder, and pervasive developmen- tal disorder into autism spectrum disorder. Symptoms of these disorders represent a single continuum of mild to severe impair ments in the two domains of social commu- nication and restrictive repetitive behaviors/ interests rather than being distinct disor-
dsm5.pdf
3ad635fe837f-1
nication and restrictive repetitive behaviors/ interests rather than being distinct disor- ders. This change is designed to improve the se nsitivity and specificity of the criteria for the diagnosis of autism spectrum disorder and to identify more focused treatment tar- gets for the specific impairments identified. •Streamlined classification of bi polar and depressive disorders. Bipolar and depres- sive disorders are the most co mmonly diagnosed conditions in psychiatry. It was there- fore important to streamline th e presentation of these disorders to enhance both clinical and educational use. Rather than separating the definition of ma nic, hypomanic, and major depressive episodes from the definition of bipolar I disorder, bipolar II disorder, and major depressive disorder as in the prev ious edition, we included all of the com- ponent criteria within the respective criteria for each disorder. This approach will facil- itate bedside diagnosis and treatment of these important disorders. Likewise, the explanatory notes for differentiating bereav ement and major depres sive disorders will provide far greater clinical guidance than was previously provided in the simple be- reavement exclusion criterion. The new specifiers of anxious distress and mixed fea- tures are now fully described in the narrativ e on specifier variations that accompanies the criteria for these disorders. •Restructuring of substance use diso rders for consistency and clarity. The categories of substance abuse and substance dependence have been eliminated and replaced with an overarching new category of substance use disorders—with the specific substance used defining the specific disorders. “Depen dence” has been easily confused with the term “addiction” when, in fa ct, the tolerance and withdrawal that previously defined dependence are actually very normal responses to prescr ibed medications that affect the central nervous system and do not necessar ily indicate the presence of an addiction.
dsm5.pdf
3ad635fe837f-2
the central nervous system and do not necessar ily indicate the presence of an addiction. By revising and clarifying these criteria in DSM-5, we hope to alleviate some of the widespread misunderstanding about these issues.
dsm5.pdf
8108bfa5b8ff-0
By revising and clarifying these criteria in DSM-5, we hope to alleviate some of the widespread misunderstanding about these issues. •Enhanced specificity for major and mild neurocognitive disorders. Given the explo- sion in neuroscience, neuropsychology, and br ain imaging over the pa st 20 years, it was critical to convey the current state-of-the-art in the diagnosis of specific types of disor- ders that were previously referred to as the “dementias” or organic brain diseases. Bi- ological markers identified by imaging for vascular and traumatic brain disorders and
dsm5.pdf
068c5f9d5c12-0
Preface xliii specific molecular genetic fi ndings for rare variants of Alzheimer’s disease and Hun- tington’s disease have greatly advanced cl inical diagnoses, and these disorders and others have now been separated into specific subtypes. •Transition in conceptualizing personality disorders. Although the benefits of a more dimensional approach to personality disorder s have been identified in previous edi- tions, the transition from a ca tegorical diagnostic system of individual disorders to one based on the relative distribution of personality traits ha s not been widely accepted. In DSM-5, the categorical personality disorder s are virtually unchan ged from the previous edition. However, an alternative “hybrid” model has been proposed in Section III to guide future research that separates interp ersonal functioning assessments and the ex- pression of pathological personality traits for six specific disorders. A more dimensional profile of personality trait expression is also proposed for a trait-specified approach. •Section III: new disorders and features. A new section (Section III) has been added to highlight disorders that requir e further study but are not sufficiently well established to be a part of the official classification of me ntal disorders for routine clinical use. Dimen- sional measures of symptom severity in 13 symptom domains have also been incorpo- rated to allow for the measurement of symp tom levels of varying severity across all diagnostic groups. Likewise, the WHO Di sability Assessment Schedule (WHODAS), a standard method for assessing global disabilit y levels for mental disorders that is based on the International Classification of Functi oning, Disability and Health (ICF) and is ap- plicable in all of medicine, has been provid ed to replace the more limited Global As- sessment of Functioning scale. It is our hope that as these measures are implemented
dsm5.pdf
068c5f9d5c12-1
sessment of Functioning scale. It is our hope that as these measures are implemented over time, they will provide greater accuracy and flexibility in the clinical description of individual symptomatic presen tations and associated disability during diagnostic as- sessments. •Online enhancements. DSM-5 features online supplemental information. Additional cross-cutting and diagnostic severity measures are available online (www.psychiatry.org/dsm5), linked to the re levant disorders. In addition, the Cul- tural Formulation Interview, Cultural Formulation Interview—Informant Version, and supplementary modules to the core Cultural Formulation Interview are also included online at www.psychiatry.org/dsm5. These innovations were designed by the leadin g authorities on mental disorders in the world and were implemented on the basis of their expert review, public commentary, and independent peer review. The 13 work group s, under the direction of the DSM-5 Task Force, in conjunction with other review bodi es and, eventually, the APA Board of Trust- ees, collectively represent the gl obal expertise of the specialty. This effort was supported by an extensive base of advisors and by the professional staff of the APA Division of Re- search; the names of everyone involved are to o numerous to mention here but are listed in the Appendix. We owe tremendous thanks to those who devoted countless hours and in- valuable expertise to this effort to improve the diagno sis of mental disorders. We would especially like to acknowledge th e chairs, text coordinators, and members of the 13 work groups, listed in the front of th e manual, who spent many hours in this vol- unteer effort to improve the scientific basis of clinical practice over a sustained 6-year pe-
dsm5.pdf
068c5f9d5c12-2
unteer effort to improve the scientific basis of clinical practice over a sustained 6-year pe- riod. Susan K. Schultz, M.D., who served as text editor, worked tirelessly with Emily A. Kuhl, Ph.D., senior science writer and DSM-5 st aff text editor, to coordinate the efforts of the work groups into a cohesive whole. Willia m E. Narrow, M.D., M. P.H., led the research group that developed the overall research stra tegy for DSM-5, including the field trials,
dsm5.pdf
c91f7b845ba2-0
the work groups into a cohesive whole. Willia m E. Narrow, M.D., M. P.H., led the research group that developed the overall research stra tegy for DSM-5, including the field trials, that greatly enhanced the eviden ce base for this revision. In addition, we are grateful to those who contributed so much time to the in dependent review of the revision proposals, including Kenneth S. Ke ndler, M.D., and Robert Freedman , M.D., co-chairs of the Scien- tific Review Committee; John S. McIntyre, M.D., and Joel Ya ger, M.D., co-chairs of the Clinical and Public Health Committee; and Glenn Martin, M.D., chair of the APA Assem-
dsm5.pdf
c421fc68cce3-0
xliv Preface bly review process. Special thanks go to Helena C. Kraemer, Ph.D., fo r her expert statistical consultation; Michael B. First, M.D., for his valuable input on the coding and review of cri- teria; and Paul S. Appelbau m, M.D., for feedback on forensic issues. Maria N. Ward, M.Ed., RHIT, CCS-P, also helped in verifying all ICD coding. The Summit Group, which included these consultants, the chairs of all review groups, the task force chairs, and the APA executive officers, chaired by Dilip V. Jeste, M.D., provided le adership and vision in helping to achieve compromise and consensus. This level of commitment has contributed to the balance and objectivity that we feel are hallmarks of DSM-5. We especially wish to recognize the outst anding APA Division of Research staff— identified in the Task Force and Work Grou p listing at the front of this manual—who worked tirelessly to interact with the task force, work groups, advisors, and reviewers to resolve issues, serve as liaison s between the groups, direct and manage the academic and routine clinical practice field trials, and record decisions in this important process. In par- ticular, we appreciate the support and guidan ce provided by James H. Scully Jr., M.D., Medical Director and CEO of the APA, throug h the years and travails of the development process. Finally, we thank the editorial and pr oduction staff of American Psychiatric Pub- lishing—specifically, Rebecca Rinehart, Publish er; John McDuffie, Edit orial Director; Ann Eng, Senior Editor; Greg Kuny, Managing Editor; and Tammy Cordova, Graphics Design
dsm5.pdf
c421fc68cce3-1
Manager—for their guidance in bringing this all together and creating the final product. It is the culmination of efforts of many talented individuals who dedicated their time, exper- tise, and passion that made DSM-5 possible. David J. Kupfer, M.D. DSM-5 Task Force Chair Darrel A. Regi er, M.D., M.P.H. DSM-5 Task Force Vice-Chair December 19, 2012
dsm5.pdf
eb474c814cbb-0
SECTION I DSM-5 Basics Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 Use of the Manual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19 Cautionary Statement for Forensic Use of DSM-5 . . . . . . . . . . . . . . . . . .25
dsm5.pdf
077f1c3bb444-0
This page intentionally left blank
dsm5.pdf
7d0721f12729-0
This section is a basic orientation to the purpose, structure, content, and use of DSM-5. It is not intended to provide an exhaustive account of the evo- lution of DSM-5, but rather to give readers a succinct overview of its key ele- ments. The introductory section descr ibes the public, professional, and expert review process that was used to extensively evaluate the diagnostic criteria presented in Section II. A summary of t he DSM-5 structure, harmonization with ICD-11, and the transition to a non-axial system with a new approach to as- sessing disability is also presented. “Use of the Manual” includes “Definition of a Mental Disorder,” forensic considerations, and a brief overview of the diag- nostic process and use of coding and recording procedures.
dsm5.pdf
5bbfc55fdaf0-0
This page intentionally left blank
dsm5.pdf
da632e691166-0
5Introduction The creation of the fifth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was a massive undertaking that involv ed hundreds of peop le working toward a common goal over a 12-year process. Much thought and deliberation were involved in evaluating the diagnostic criter ia, considering the organization of every aspect of the man- ual, and creating new features believed to be mo st useful to clinicians. All of these efforts were directed toward the goal of enhancing th e clinical usefulness of DSM-5 as a guide in the diagnosis of mental disorders. Reliable diagnoses are essential for guidin g treatment recommendations, identifying prevalence rates for mental health service pl anning, identifying patient groups for clinical and basic research, and documenting importan t public health information such as mor- bidity and mortality rates. As the understand ing of mental disorders and their treatments has evolved, medical, scientific, and clinical professionals have focused on the character- istics of specific disorders and their im plications for treatment and research. While DSM has been the cornerstone of substant ial progress in reliability, it has been well recognized by both the American Psychiatric Association (APA) and the broad scientific com- munity working on mental diso rders that past science was no t mature enough to yield fully validated diagnoses—that is, to provide consistent, strong, and objective scientific validators of individual DSM disorders. The science of mental disorders continues to evolve. However, the last two decades since DSM-IV was released have seen real and durable progress in such areas as cognitive neuroscience , brain imaging, epidemiology, and genetics. The DSM-5 Task Force overseeing the new edition recognized that research advances will require careful, iter- ative changes if DSM is to maintain its place as the touchstone classifi cation of mental disor-
dsm5.pdf
da632e691166-1
ders. Finding the right balance is critical. Speculative results do not belong in an official nosology, but at the same time, DSM must evolve in the context of other clinical research ini- tiatives in the field. One important aspect of this transition derives from the broad recognition that a too-rigid categorical system does not capt ure clinical experience or important scientific observations. The results of nu merous studies of comorbidity and disease transmission in fam- ilies, including twin studies and molecular genetic studies, make strong arguments for what many astute clinicians have long observed: the boundaries between many disorder “catego- ries” are more fluid over the li fe course than DSM-IV recognized, and many symptoms as- signed to a single disorder may occur, at vary ing levels of severity, in many other disorders. These findings mean that DSM, like other medi cal disease classifications, should accommo- date ways to introduce dimens ional approaches to mental di sorders, including dimensions that cut across current categories. Such an appr oach should permit a more accurate description of patient presentations and increase the validity of a diagnosis (i.e., the degree to which diag- nostic criteria reflect the comprehensive mani festation of an underlying psychopathological disorder). DSM-5 is designed to better fill the need of clinicians, patients, families, and re- searchers for a clear and concise description of ea ch mental disorder organized by explicit di- agnostic criteria, supplemented, when approp riate, by dimensional measures that cross diagnostic boundaries, and a brie f digest of information about th e diagnosis, risk factors, as- sociated features, research advances, and various expressions of the disorder. Clinical training and experience are needed to use DSM for determining a diagnosis. The diagnostic criteria identify symptoms, behavior s, cognitive functions, personality traits, phys-
dsm5.pdf
5d5b1d6a8926-0
Clinical training and experience are needed to use DSM for determining a diagnosis. The diagnostic criteria identify symptoms, behavior s, cognitive functions, personality traits, phys- ical signs, syndrome combinations, and durations that require clinical expertise to differenti- ate from normal life variation and transient responses to stress. To facilitate a thorough
dsm5.pdf
8cfc1978f0db-0
6 Introduction examination of the range of symptoms present, DSM can serve clinicians as a guide to identify the most prominent symptoms that should be assessed when diagnosing a disorder. Although some mental disorders may have well-defined boundaries around symptom clusters, scien- tific evidence now places many, if not most, disorders on a spectrum with closely related dis- orders that have shared symptoms, shared genetic and environmental risk factors, and possibly shared neural substrates (perhaps most strongly established for a subset of anxiety disorders by neuroimaging and animal models). In short, we have come to recognize that the boundaries between disorders are more porous than originally perceived. Many health profession and educational groups have been involved in the development and testing of DSM-5, including physicians, psychologists, social workers, nurses, counselors, epidemiologists, statisticians, neuroscientists, and neuropsychologists. Finally, patients, fam- ilies, lawyers, consumer organizations, and advoca cy groups have all participated in revising DSM-5 by providing feedback on the mental di sorders described in this volume. Their moni- toring of the descriptions and explanatory text is essential to improve understanding, reduce stigma, and advance the treatment and eventual cures for these conditions. A Brief History The APA first published a predecessor of DSM in 1844, as a statistical classification of in- stitutionalized mental patients. It was designed to improve co mmunication about the types of patients cared for in these hospitals. This forerunner to DSM also was used as a component of the full U.S. census. After World War II, DSM evolved through four major editions into a diagnostic classification system for psychiatrists, other physicians, and other mental health professionals that descri bed the essential features of the full range of
dsm5.pdf
8cfc1978f0db-1
other mental health professionals that descri bed the essential features of the full range of mental disorders. The current ed ition, DSM-5, builds on the go al of its predecessors (most recently, DSM-IV-TR, or Text Revision, published in 2000) of providing guidelines for di- agnoses that can inform treatment and management decisions. DSM-5 Revision Process In 1999, the APA launched an evaluation of the strengths and weaknesses of DSM based on emerging research that did not support the bo undaries established for some mental disor- ders. This effort was coordinated with the World Health Organization (WHO) Division of Mental Health, the World Psychiatric Associat ion, and the National Institute of Mental Health (NIMH) in the form of several conferen ces, the proceedings of which were published in 2002 in a monograph entitled A Research Agenda for DSM-V. Thereafter, from 2003 to 2008, a cooperative agreement with the APA and th e WHO was supported by the NIMH, the Na- tional Institute on Drug Abuse (NIDA), and the National Institute on Alcoholism and Alco- hol Abuse (NIAAA) to convene 13 internatio nal DSM-5 research planning conferences, involving 400 participants from 39 countries, to review the world litera ture in specific diag- nostic areas to prepare for revision s in developing both DSM-5 and the International Classi- fication of Diseases, 11th Revision (ICD-11). Reports from these conferences formed the basis for future DSM-5 Task Force reviews and set the stage for the new edition of DSM.
dsm5.pdf